NEOANTIGEN
VACCINES
Neoantigen vaccines take the exact genetic mutations in a patient's tumor and use them as the active ingredient. Your immune system gets trained against the specific abnormal proteins your cancer produces. Nobody else's neoantigen vaccine is the same as yours โ that's the entire point.
What This Means for Patients
Cancer cells are genetically broken. They accumulate mutations that cause them to produce abnormal proteins โ neoantigens โ that normal, healthy cells don't make. Those abnormal proteins sit on cancer cell surfaces like flags that, in theory, the immune system should recognize as foreign. The problem is that tumors suppress immune activity in surrounding tissue, so even visible flags get ignored. A neoantigen vaccine introduces exactly those proteins โ from your specific tumor's mutations โ in a controlled way, training the immune system to identify and destroy cells carrying them.
Key Things to Understand
Four practical realities about how neoantigen vaccines are built, delivered, and used.
Genomic Sequencing Is Where It Starts
A tumor biopsy and blood sample are both sequenced โ comparing the two identifies which mutations are unique to the cancer. Not all mutations make good vaccine targets. Algorithms rank which produce the most immune-targetable neoantigens, and those become the vaccine's ingredients.
Manufacturing Takes 4โ8 Weeks
Custom production via mRNA or peptide platform โ each vaccine unique to each patient. That is a real timeline to account for in treatment planning. Disease stability during the manufacturing window matters significantly.
Combination With Checkpoint Inhibitors Is Standard
Almost all current neoantigen vaccine protocols include checkpoint inhibitors. The vaccine trains the immune response. The checkpoint inhibitor prevents the tumor from chemically shutting it down. The combination consistently outperforms either alone.
Most Access Is Through Clinical Trials
No commercial approvals yet. Trial enrollment is the current pathway โ with all that entails: eligibility criteria, specialized centers, timelines, and capacity limits. Starting the conversation earlier gives more realistic options.
What the Data Actually Shows
- ~44%Recurrence/Death Reduction โ Melanoma Phase IImRNA-4157/V940 plus pembrolizumab vs pembrolizumab alone in high-risk resected melanoma (KEYNOTE-942). Consistent at extended follow-up. Advanced directly to Phase III.
- PancreaticT-Cell Responses DocumentedIn a cancer type that has historically shown almost zero response to immunotherapy, genuine T-cell responses against neoantigen targets were observed โ changing how researchers think about what's possible.
- Phase IIImRNA-4157/V940 StatusThe Moderna/Merck neoantigen vaccine program is now in Phase III for melanoma โ the most advanced personalized neoantigen vaccine program running anywhere in the world.
Who This Is Relevant For
Patients with solid tumors โ melanoma, lung cancer, pancreatic cancer, colorectal cancer, bladder cancer โ who have undergone genomic sequencing and show high tumor mutational burden. Prior immunotherapy failure isn't a disqualifier โ it's frequently a requirement in these trials. The combination of failed checkpoint inhibitor therapy and high TMB is often the profile these programs are specifically designed to enroll.
Benefits and Limitations
Benefits
- Most precise targeting possibleTargeting your tumor's exact genetic makeup โ not generic cancer markers shared across millions of patients โ gives the immune response the best chance of producing lasting memory.
- Consistent cross-cancer signalsPhase II results moving in the same direction across melanoma, pancreatic cancer, and others โ not isolated to one cancer type.
- Multi-neoantigen approach makes evasion harderTargeting many mutation sites simultaneously makes it significantly harder for the tumor to escape by losing any single marker.
Limitations
- Not every tumor produces sufficient targetsLower mutational burden means fewer candidate neoantigens. Genomic analysis tells you which situation you are in โ it is not a guess.
- Manufacturing is complex and time-dependentFour to eight weeks minimum. Disease must be stable or manageable during that window. Bridging therapy discussions are part of the planning.
- Tumor microenvironment can still limit efficacyEven a precisely designed vaccine can be dampened by active immune suppression at the tumor site. Combination strategies address this partially.
Frequently Asked Questions
Neoantigen Vaccine Questions
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Do Your Genomic Sequencing Results Include Neoantigen Target Data?
Neoantigen vaccine eligibility begins with knowing your tumor's actual mutations. Upload your genomic profiling results and our specialist team will assess which programs are relevant to your specific case.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.